Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) ...

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

Previously, CGMs have only been available as medical devices for people ... which announced the US availability of its own prescription-free CGM shortly after Dexcom had cleared its own.) ...

Ascensia Diabetes Care, a global diabetes care company, announces that it is launching the Eversense ® 365 continuous glucose monitoring (CGM ... ("Senseonics") is a medical technology company ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

CMA CGM has declared force majeure over a strike that has closed container terminals across a major swathe of the US ...

The case for Abbott Laboratories. Abbott Laboratories is one of the world's leading medical device makers. It routinely ...

Senseonics Holdings, Inc. (NYSE American: SENS) ("Senseonics" or the "Company"), a medical technology company focused on the ...

Opens in a new tab or window The FDA cleared Eversense 365 as the first 1-year integrated continuous glucose monitoring (CGM) system for adults with type 1 or type 2 diabetes, said maker Senseonics.

In recent years, digital health has become a new development trend in the global health and medical industry. By using ...

CompuGroup Medical (CGM) has appointed Dr. Thomas Speckmann as its Global Head of Communications, starting November 1, 2024.